We sought to determine whether valdecoxib is as effective as diclofenac in treating acute ankle sprain. Patients (n = 202) with acute first-and seconddegree ankle sprain were randomized to valdecoxib (40 mg twice daily on day 1 followed by 40 mg once daily on days 2 -7) or diclofenac (75 mg twice daily). The primary efficacy end-point was the Patient's Assessment of Ankle Pain visual analogue scale (VAS, 0 -100 mm) value on day 4. Valdecoxib was as efficacious as diclofenac in treating the signs and symptoms of acute ankle sprain. The mean VAS reduction in ankle pain on day 4 was not different between groups; the two-sided 95% confidence interval for the betweengroup difference was within the prespecified limit for non-inferiority (10 mm). There were no significant differences between groups for all secondary efficacy end-points. The two treatments were similarly effective and well tolerated for treatment of acute ankle sprain. KEY WORDS: VALDECOXIB; DICLOFENAC; CYCLOOXYGENASE (COX)-2 INHIBITORS; ANKLE SPRAIN; PAIN JA Diaz, C Cuervo, AM Valderrama et al. Pain relief with valdecoxib after acute ankle sprain JA Diaz, C Cuervo, AM Valderrama et al. Pain relief with valdecoxib after acute ankle sprain •
Introduction
Ankle sprains constitute the largest percentage of musculo-skeletal injuries, with estimates of up to 27 000 ankle injuries daily in the USA. 1 Ankle sprains vary in severity and, although most patients return to normal function and activity shortly after an ankle sprain, some patients may experience residual signs and symptoms that can negatively affect daily and recreational activities for several years. 2 − 4 In addition to swelling and loss of motion, ankle sprains are also associated with inflammation, oedema, pain and erythema. 5 Oedema in the surrounding area can compound tissue damage, delay healing and contribute to chronic disability. 6 Therefore, the goals of treatment are to decrease pain and inflammation, prevent swelling and maintain the range of motion. Clinical trials have also shown that treatment with nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2selective inhibitors can ameliorate pain, reduce inflammation and help speed the return to full function. 7 − 13 Non-selective NSAIDs inhibit both isoforms of the COX enzyme, COX-1 and COX-2. Although they are effective analgesics, they are also associated with gastrointestinal toxicity 14 − 18 and negative effects on platelet function, 19 − 22 which occur as a result of COX-1 inhibition. In the context of ankle sprains, the use of non-selective NSAIDs may Pain relief with valdecoxib after acute ankle sprain increase the risk of haematoma, which could slow healing and the return to normal daily function. 9 In contrast, COX-2-selective inhibitors do not inhibit COX-1 at therapeutic doses. They have anti-inflammatory and analgesic effects comparable to those of non-selective NSAIDs, but with superior gastrointestinal and platelet safety. 14 − 18,20 − 22 The COX-2-specific inhibitor valdecoxib has demonstrated efficacy in relieving the signs and symptoms associated with osteoarthritis and adult rheumatoid arthritis. 17,18,23 − 25 Valdecoxib has also shown efficacy in the management of acute pain. 10,26 − 29 Diclofenac is a non-selective NSAID used for the treatment of mild-to-moderate pain in patients with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculo-skeletal pain. 30 − 32 Although diclofenac is generally well tolerated, it is also associated with gastrointestinal adverse events, and is administered with meals to limit gastrointestinal toxicity. 31, 32 Placebocontrolled, comparative studies have shown that diclofenac is effective in the treatment of acute ankle sprain and results in a decrease in functional impairment. 33 − 35 The primary objective of the present study was to determine whether valdecoxib (40 mg twice daily on day 1, followed by 40 mg once daily on days 2 -7) was as effective as diclofenac (75 mg twice daily) for the treatment of acute first-and seconddegree ankle sprain.
Patients and methods

STUDY POPULATION
Patients aged ≥ 18 years with acute first-or second-degree ankle sprain of the lateral aspect, specifically the anterior talofibular ligament and/or calcaneofibular ligament, were eligible to participate in the study, provided the injury was sustained no more than 48 h before the first dose of study medication. Diagnosis of first-or seconddegree ankle sprain was based on a standard definition of ankle sprain in addition to a test for ankle joint stability. Patients were required to have moderate-tosevere ankle pain on full weight bearing, determined by a score of ≥ 45 mm on the Patient's Assessment of Ankle Pain visual analogue scale (VAS), which ranged from 0 (no pain) to 100 mm (severe pain). Patients were also required to have a rating of at least 2 on both the Patient's Global Assessment of Ankle Injury and the Patient's Assessment of Normal Function/Activity. The Patient's Global Assessment of Ankle Injury is a five-point scale ranging from 1 (very mild signs and symptoms of ankle sprain) to 5 (very severe signs and symptoms of ankle sprain), and the Patient's Assessment of Normal Function/Activity is a five-point scale ranging from 1 (normal walking/activity and no pain) to 5 (severely restricted walking because of pain and inability to resume normal activities).
Patients with a previous injury of the same joint within the last 6 months, thirddegree sprain (clinical evidence of complete rupture of ankle ligaments), ipsilateral ankle and knee injury or bilateral ankle injury were excluded. Also excluded were patients requiring bed rest, hospitalization, surgical intervention for ankle injury or a non-removable full cast, patients who had used any anti-inflammatory medications within 24 h of the first dose of the study medication, any analgesic within 6 h of the first dose of the study medication or oral intra-muscular corticosteroids within 30 days of the study medication, and patients who had received an intra-articular injection within 8 weeks of the study medication. Patients who took the following medications within 24 h prior to the initial dose of study medication were also excluded: topical, oral Pain relief with valdecoxib after acute ankle sprain or injectable NSAIDs; analgesics including opioids and tramadol; muscle relaxants; neuroleptics; tricyclic antidepressants; sedative hypnotics; and anxiolytics. Patients were also excluded if it was determined that they would be likely to take diuretics, anticoagulants, lithium, digoxin or anti-ulcer medications at any time throughout the course of the study. Aspirin ≤ 325 mg daily for cardioprotection was allowed. Patients were also excluded if they had active gastrointestinal disease (such as Crohn's disease or ulcerative colitis), a contraindication to NSAID use, upper gastrointestinal ulceration within 30 days of study initiation, clinically significant renal or hepatic disease, osteoarthritis under active therapy, rheumatic disease, or a history of substance abuse.
The study was approved by an institutional review board or independent ethics committee in accordance with the legal and regulatory requirements of each of the five countries in which the study centres were located. Each study centre had its own insitutional review board approve the study. There were three centres in Argentina, seven in Colombia, three in Chile, one in Mexico and three in Peru. The study was conducted in accordance with Good Clinical Practice 36 and with the regulatory requirements of the country in which the study was conducted. Prior to enrolment, written informed consent was obtained from each patient.
STUDY DESIGN
This was a multicentre, randomized, doubleblind, 7-day, comparative trial. At each site, eligible patients were randomized in a 1:1 ratio to valdecoxib 40 mg twice daily on day 1 followed by 40 mg once daily on days 2 -7 or diclofenac 75 mg twice daily for 7 days in the order in which they were enrolled into the study. Patients received the first dose of study medication as soon as possible after randomization on day 1. Double-blind treatment continued for 7 days, with study visits on day 4 and day 7 (± 1 day) or at the time of early withdrawal. Standard-of-care non-pharmacological interventions were allowed: crutches, canes, contrast baths, ankle taping or brace, air cast, transcutaneous electrical nerve stimulation, diathermy, massage therapy, ultrasound, acupuncture and strengthening/proprioceptive exercises. Traditional therapy using rest, ice, compression and elevation (RICE) was also permitted.
The following assessments were completed on each day of the trial: Patient's and Physician's Global Assessment of Ankle Injury, Patient's Assessment of Ankle Pain VAS, Patient's and Physician's Satisfaction Assessment with study medication.
EFFICACY AND SAFETY END-POINTS
The primary efficacy end-point was the Patient's Assessment of Ankle Pain VAS value on day 4. Secondary efficacy end-points included: Patient's Assessment of Ankle Pain VAS value on day 7; Patient's and Physician's Global Assessment of Ankle Injury on days 4 and 7; time to return to normal function/activity; time to onset of pain relief after the first dose (0, 15, 30, 45 and 60 min after the first dose on day 1); and Patient's and Physician's Satisfaction Assessments (10-point scale ranging from 1 = very unwilling to use the same medication for an ankle injury to 10 = very willing) on day 7. In addition, patients recorded the following information daily: number of study medication tablets ingested; Patient's Assessment of Normal Function/Activity (five-point scale ranging from 1 = normal walking/activity and no pain to 5 = severely restricted walking); and over-the-counter and prescription medications taken. All adverse events were reported during the 7-day study. Pain relief with valdecoxib after acute ankle sprain
STATISTICAL ANALYSIS
The sample size was determined on the basis of the primary efficacy end-point, the Patient's Assessment of Ankle Pain VAS value on day 4. The maximum clinically acceptable difference for declaring noninferiority was 10 mm on this VAS scale of 0 -100 mm. Assuming a SD of 23 mm, this study had 80% power with 85 evaluable patients per study medication group to reject the hypothesis that valdecoxib was inferior to diclofenac and accept the alternative hypothesis that valdecoxib is clinically noninferior to diclofenac. Allowing for nonevaluable patients, the sample size needed for the study was 200 in total or 100 per study group.
Two-sided 95% confidence intervals were calculated for all populations when appropriate. For testing non-inferiority of the primary efficacy end-point, the evaluable population and modified intention-to-treat (mITT) populations were used, and the mITT population was used for all the secondary analyses. The mITT analyses included patients who were randomized, received at least one dose of study medication and had at least one follow-up efficacy measure that included the Patient's Assessment of Ankle Pain VAS score on weight bearing. A general linear fixed-effects model was used to test non-inferiority, with treatment, centre and baseline severity (moderate or severe) as covariates. Fisher's exact test and, when needed, logistic regression were used for categorical variables. Cochran-Mantel-Haenszel statistics were used to analyse categorical responses. P-values < 0.05 were considered to be statistically significant.
Results
PATIENT BASELINE CHARACTERISTICS AND DISPOSITION
A total of 202 patients were enrolled into the study (Fig. 1 ). All 101 patients randomized to valdecoxib, and 100 of the 101 patients randomized to diclofenac were included in the mITT analysis. Three patients (3.0%) from the valdecoxib group and eight (7.9%) from the diclofenac group withdrew from the study. The main reasons for discontinuation were adverse events (dizziness, gastritis, phalangeal fracture and rash; two patients from each treatment group) and protocol non-compliance (five patients from the diclofenac group). Among the five diclofenac-treated patients who were non-compliant, one lost the treatment diary and two were lost to follow-up; the reason for non-compliance in the other two was unrecorded. Baseline demographic characteristics are described in Table 1 and were comparable between groups.
EFFICACY ANALYSIS
Valdecoxib was as efficacious as diclofenac in treating the signs and symptoms of acute first-or second-degree ankle sprain. The least-squares mean value for the Patient's Assessment of Ankle Pain VAS was approximately 33 mm for both treatment groups on day 4, representing reductions of approximately 40 mm from baseline (Fig. 2) . The mean reduction in Patient's Assessment of Ankle Pain VAS at day 4 was comparable in the two treatment groups; the two-sided 95% confidence interval for the between-group mean difference in the VAS value was within the pre-specified limit of non-inferiority, 10 mm. There was also no significant difference between treatment groups in the mean reduction in Patient's Assessment of Ankle Pain VAS from baseline at day 4 in patients for whom baseline ankle pain was categorized as moderate (VAS, 45 -60 mm) or severe (VAS, > 60 mm) ( Table 2) .
The results for all secondary efficacy endpoints were similar for the two treatment groups, with no statistically significant differences. For both treatment groups, the least-squares mean of the Patient's Assessment of Ankle Pain VAS value at
TABLE 2: Patient's Assessment of Ankle Pain visual analogue scale (VAS) (mm) at baseline and on day 4 categorized by severity of pain in the modified intention-to-treat (mITT) population
Valdecoxib a Diclofenac b (n = 101) (n = 100)
Moderate pain at baseline c Baseline, n (%) 33 Mean VAS pain Pain relief with valdecoxib after acute ankle sprain day 7 had decreased from the baseline value by approximately 55 mm (to ≈14 mm) and was not significantly different between the two groups.
There was a clear reduction in Patient's Assessment of Ankle Pain VAS during the first post-treatment hour for both treatment groups (Fig. 3) , and most patients returned to normal function and activity by day 7 (Fig. 4) . On the basis of the Physician's Global Assessment of Ankle Injury, only a small percentage of patients were assessed as either having no change or becoming worse by day 7 (6.0% and 7.4% in the valdecoxib and diclofenac groups, respectively; not significant). In the patients' self-assessments, only 4.2% in the valdecoxib group indicated poor or very poor improvement, compared with 2.3% in the diclofenac group (not significant). Patient's and Physician's Satisfaction Assessments were high for both treatment groups. At day 7, approximately 80% of patients and physicians reported a satisfaction score of 8 -10, indicating that most were willing or very willing to use the medication again ( Fig. 5 ).
SAFETY AND TOLERABILITY
Valdecoxib and diclofenac were well tolerated. Adverse events were mild to moderate in intensity, with no severe adverse events reported ( Table 3 ). The most common adverse event in both groups was gastritis. One patient in the diclofenac group considered the gastritis to be moderate in intensity; all other cases of gastritis were mild in intensity. Two patients in each group thought that their gastritis was treatment related. Dyspepsia was the second most frequently reported adverse event; two patients in the valdecoxib group judged their dyspepsia to be treatment related. Two patients from each group discontinued the study because of adverse events. The valdecoxib-treated patients discontinued because of an allergic rash and dizziness; both events were considered moderate and probably related to treatment. The two diclofenac-treated patients discontinued because of a phalangeal fracture and moderate gastritis judged to be related to treatment.
Discussion
Ankle sprains cause significant discomfort and functional impairment. Therefore, the overall goals of treatment are to provide rapid and effective relief of pain and inflammation and a rapid return to normal function. This multicentre, randomized, double-blind, comparative study showed that treatment for 7 days with valdecoxib 40 mg twice daily on day 1 followed by 40 mg once daily on days 2 -7 was as efficacious as diclofenac 75 mg twice daily for 7 days in reducing the signs and symptoms of acute first-or second-degree ankle sprain. In both treatment groups, the patient's ankle pain was markedly decreased during the first hour of treatment (by ~10 mm on a 100-mm VAS), and by day 4 there was a pain reduction in VAS scores of approximately 50% compared with baseline. Importantly, this latter observation is consistent with studies showing that a reduction in VAS scores of 33 − 50% or more from baseline is clinically meaningful. 37, 38 Valdecoxib and diclofenac were also equally effective on all secondary endpoints, including satisfaction with treatment; most patients in both treatment groups returned to normal function by day 7. The results presented here also confirm the results of previous studies which have demonstrated that COX-2-selective inhibitors, when used with standard nonpharmacological treatments, such as RICE, can relieve pain and inflammation and speed a return to normal function. 9,10,12 A previous study with valdecoxib found that it was comparable to tramadol and significantly better than placebo in relieving ankle pain, and valdecoxib enabled more patients to resume normal walking. 10 Valdecoxib also showed better tolerability than tramadol, with fewer upper gastrointestinal and central nervous system events and fewer withdrawals. Generally, the use of valdecoxib has resulted in fewer gastrointestinal adverse events than the use of non-selective NSAIDs in clinical trials. 14 -18 For the New Drug Application (NDA), the completed arthritis trials were pooled. It is generally true that valdecoxib is associated with a somewhat better gastrointestinal tolerability profile than NSAIDs. Overall, valdecoxib 10 -40 mg daily compared favourably with pooled NSAIDs for gastrointestinal adverse events, although this was dependent on the doses of valdecoxib and the comparator used and the specific type of event. There were a few studies in which significantly more individual gastrointestinal adverse events were reported by patients treated with valdecoxib compared with a non-selective NSAID. 39 Following the completion of the present study, sales of valdecoxib were suspended in the USA at the request of the Food and Drug Administration, and subsequently in most countries worldwide. The agency stated that this request was due to a lack of adequate data on the cardiovascular safety of long-term valdecoxib use, reports of serious skin reactions, including deaths, that are unpredictable, and the lack of any demonstrated advantages compared with other NSAIDs. 40 In addition to a short recovery time, patients also want rapid relief of pain, as well as a medication that is tolerable. 8 Previous studies have confirmed that diclofenac is effective and generally well tolerated for the treatment of ankle sprain. 8,33 − 35,41 However, it is also frequently associated with gastro-intestinal adverse events, 31, 32 and one study in patients with traumatic joint distortion, primarily of the ankle, found that 70% of reported adverse events associated with diclofenac treatment were gastrointestinal complaints. 35 Although the present study did not demonstrate a significant difference between valdecoxib and diclofenac in terms of adverse gastrointestinal events, previous studies in patients with osteoarthritis or rheumatoid arthritis have shown that diclofenac is associated with significantly greater gastrointestinal toxicity than valdecoxib. 14, 17, 18 In addition, valdecoxib does not have any significant effect on platelet aggregation, even at supra-therapeutic doses; 21, 22 a comparative study of valdecoxib and diclofenac found that diclofenac significantly reduced platelet aggregation while valdecoxib had no effect. 22 In conclusion, this study demonstrates that valdecoxib 40 mg daily was as effective and well tolerated as diclofenac 75 mg twice daily in treating the signs and symptoms of acute first-and second-degree ankle sprain. These findings suggest that COX-2 selective inhibitors such as valdecoxib are effective in the early treatment of ankle sprain injuries.
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